INDO US BIOTECH
Back to Income Statement
|
INDO US BIOTECH Last 5 Year Revenue History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹104 Cr | ₹73 Cr | ₹62 Cr | ₹50 Cr | ₹40 Cr |
What is the latest Revenue of INDO US BIOTECH ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹104 Cr |
| Mar2024 | ₹73 Cr |
| Mar2023 | ₹62 Cr |
| Mar2022 | ₹50 Cr |
| Mar2021 | ₹40 Cr |
How is Revenue of INDO US BIOTECH Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹104 Cr | 42.56 | |
| Mar2024 | ₹73 Cr | 17.96 | |
| Mar2023 | ₹62 Cr | 23.36 | |
| Mar2022 | ₹50 Cr | 24.86 | |
| Mar2021 | ₹40 Cr | - | |
Compare Revenue of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹249.9 Cr | -7.3% | -1.9% | -50% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹13,777.9 Cr | 7.1% | 7.2% | -31.1% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹5,157.5 Cr | 3.7% | 0.4% | 20.3% | Stock Analytics | |
| VENKYS (INDIA) | ₹1,884.7 Cr | 0.4% | -8.7% | -23.1% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,197.4 Cr | -3.5% | -7.1% | -27.2% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹480.8 Cr | 7.6% | -2.2% | 21.2% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -7.3% |
-1.9% |
-50% |
| SENSEX | 1% |
2.5% |
6.5% |
You may also like the below Video Courses